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Abstract
In order to provide comprehensive information on the differences in bioactivity between human insulin and insulin
analogues, published in vitro comparisons of human insulin and the rapid acting analogues insulin lispro
(Humalog
®), insulin aspart ( NovoRapid
®), insulin glulisine (Apidra
®), and the slow acting analogues insulin glargine
(Lantus
®), and insulin detemir (Levemir
®) were gathered from the past 20 years (except for receptor binding
studies). A total of 50 reports were retrieved, with great heterogeneity among study methodology. However,
various differences in bioactivity compared to human insulin were obvious (e.g. differences in effects on
metabolism, mitogenesis, apoptosis, intracellular signalling, thrombocyte function, protein degradation). Whether or
not these differences have clinical bearings (and among which patient populations) remains to be determined.
Introduction
Since the first insulin derivatives were synthetised in the
1970s for scientific purposes [1,2], the therapeutic poten-
tial of these compounds for diabetic patients was already
under investigation. In those times, there was a quest for
metabolically superactive insulins, i.e. “tailor-made” insu-
lin derivatives with enhanced biopotency, like the insulin
derivative B10Asp [3], to make the treatment of diabetes
mellitus more efficacious [3]. And B10Asp was indeed
prepared to be marketed. In 1992 (when the carcinogeni-
c i t yo fB 1 0 A s p[ 4 ]w a sd i s c l o s e db yh a p h a z a r d )i tw a s
realized that manipulations of the insulin molecule could
introduce the risk of artificial bioactivities into the treat-
ment of diabetic patients [4-6]. Probably because of such
concerns, insulin manufacturers subsequently favoured
the design of derivatives (euphemistically called insulin
analogues) with particular absorption properties (i.e. fas-
ter or more prolonged absorption from the subcutaneous
tissue after injection [7,8]). Since 1996, five of such insu-
lin analogues have been approved for human use (the
rapid acting analogues aspart, glulisine and lispro, and
the slow-acting analogues glargine and detemir). Their
biological potencies still remain to be fully elucidated [4].
In order to expose the known differences in all fields of
bioactivity between these insulin analogues and human
insulin, we registered all in vitro studies - except for
receptor binding studies - published from 1990 to 2010
and displayed their findings schematically in the follow-
ing report.
Materials and methods
An electronic search was conducted in the PubMed data-
base using the following key words: in vitro, proliferation,
mitogenic, mitogenicity, metabolic, apoptosis, potency,
glucose transport, lipogenesis, intracellular signalling, in
conjunction with the currently marketed insulin analo-
gues searched for by their international non-proprietary
names: insulin aspart [B28Asp human insulin] (Novo-
Nordisk, Bagsvaerd, Denmark), insulin detemir [B29Lys
(epsilon-tetradecanoyl), desB30 human insulin] (Novo-
Nordisk, Bagsvaerd, Denmark), insulin glargine [A21Gly,
B31Arg,B32Arg human insulin] (Sanofi-Aventis, Paris,
France), insulin glulisine [B3Lys,B29Glu human insulin]
(Sanofi-Aventis, Paris, France) and insulin lispro [B28Lys,
B29Pro human insulin] (Eli Lilly, Indianapolis, IN, USA).
Their respective brand names Humalog
®, NovoRapid
®,
Lantus
®, Apidra
®, Levemir
® and their company abbrevia-
tions HOE 901(= Lantus
®), NN 304(= Levemir
®), HMR
1964 (= Apidra
®), B28Asp (= NovoRapid
®)a n d
LY275585(= Humalog
®) were also searched for. A hand
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posium reports, and abstract volumes of scientific meet-
ings. The time span covers the years 1990 to 2010.
Receptor binding studies were not addressed in this
search. The publications are reported in a schematic
fashion, in alphabetical order of the analogues’ interna-
tional non-proprietary names.
Results
Altogether, 50 publications were retrieved reporting in
vitro data on comparisons between human (native) insu-
lin and one of the insulin analogues indicated above
[5,9-57]. There were 45 full papers [5,9,21,23-27,31-
38,40-57] and 5 abstracts [22,28-30,39]. The publications
were screened for differences in seven categories: meta-
bolic activity, mitogenic activity, anti-apoptotic activity,
intracellular signalling, effects on thrombocytes, effects
on protein degradation, and intracellular internalization.
The studies were performed or sponsored by pharmaceu-
tical companies (n = 27) or independent institutions
[10,12,16-18,27,31-34,37,39,41-43,55-57]; in 3 studies,
possible sponsoring could not be identified.
Differences in metabolic activity
There were 14 publications reporting in vitro studies on
the metabolic activity of insulin analogues (assessed in
primary mouse adipocytes, primary rat cardiomyocytes
and adipocytes, human muscle cells, human dermal
microvascular endothelial cells, 3T3-L1 adipocytes, and
L6 myocytes) in comparison to synthetic human insulin.
Aspart
This issue was addressed in the Scientific Discussion of
insulin aspart, published by the European Medicines
Agency (EMEA) (page 4: “in mouse free fat cells, the sti-
mulation of lipogenesis did not differ between insulin
aspart and human insulin, lending further support to
similar molar potency” [58]). In primary rat adipocytes,
the effects on glucose transport and lipogenesis were
similar to human insulin [21], and in primary mouse adi-
pocytes the effect on lipogenesis was similar to human
insulin [26,53].
Detemir
This issue was addressed in the Scientific Discussion of
insulin detemir, published by the EMEA (pages 1-6:
“insulin detemir was consistently less potent than human
insulin in all in vitro assays. Depending on the assay, the
potency was 2- to 10-fold lower” [59]). In primary mouse
adipocytes [26] and primary rat adipocytes [48], in 3T3-
L1 adipocytes [12,54] and in L6 myocytes [54] the meta-
bolic potency was only 1-20% of that of human insulin by
equimolar comparison. (Therefore, the manufacturer
increased the concentration of the active substance in the
vial four-fold compared to synthetic human (or porcine
natural) insulin [48]: 1 unit of human insulin is 6 nmol
insulin, while 1 unit of insulin detemir is 24 nmol [59]).
Glargine
This issue was addressed in the Scientific Discussion of
insulin glargine, published by the EMEA (page 5: “nearly
all in vitro metabolic studies have shown a relative in
vitro potency for insulin glargine of about 50% and simi-
lar maximal responsiveness as compared to human insu-
lin....there is evidence that higher plasma levels in vivo
compensate for the 50% in vitro potency found for insu-
lin glargine as compared to human insulin”[60]). In pri-
mary mouse adipocytes [26], primary rat cardiomyocytes
[9,46] and in 3T3-L1 adipocytes [19,25] metabolic
potency was only about 50% of that of human insulin by
equimolar comparison. Another study in 3T3L1 adipo-
cytes showed a similar metabolic potency to human
insulin [55]. In non-starved muscle cells, the effect on
glucose uptake was similar to human insulin [14]. In
human dermal microvascular endothelial cells, there was
no effect, similar to human insulin [13].
Glulisine
This issue was addressed in the Scientific Discussion of
insulin glulisine, published by the EMEA (page 8: “Stimu-
lation of glucose transport was equal for both insulin glu-
lisine and human insulin...lipogenic activity and glucose
transport in isolated rat adipocytes was slightly lower
than human insulin, but reached the same maximum
obtainable effects as human insulin at higher concentra-
tions”[61]). In rat cardiomyocytes, the effect on glucose
transport [35], and in non-starved muscle cells, the effect
on glucose uptake [15] was similar to human insulin.
Lispro
This issue was addressed in the Scientific Discussion of
insulin lispro, published by the EMEA (page 2: “Insulin
lispro is biologically equivalent to insulin in several in
vitro tests, including ...glucose transport in adipocytes”
[62]). In primary mouse adipocytes [26] the effect on
lipogenesis was comparable to that of human insulin. A
study in L6 myotubes showed a similar metabolic
potency compared to human insulin [47].
Differences in mitogenic activity
As standard 2-year carcinogenicity in vivo studies in ani-
mals (see EMEA: Note for Guidance on Carcinogenic
Potential; CPMP/SWP/2877/00) have not been per-
formed with any of the commercially available insulin
analogues (except for insulin glargine [58-62]), the issue
of mitogenicity has been addressed by quite a few in
vitro investigations. There were 34 publications report-
ing in vitro data on the mitogenic activity of insulin ana-
logues with various non-malignant cell types: primary
muscle cells, human smooth muscle cells, Chinese ham-
ster ovary cells (CHO-K1), human dermal microvascular
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H9c2 myoblasts, H9 cardiac myoblasts, rat-1 fibroblasts,
rat H4-II-E hepatoma cells, K6 myoblasts, L6 myoblasts,
HepG2 cells, C2C12 myoblasts, mammary gland-derived
MCF-10 cells, human coronary artery endothelial cells,
human coronary artery smooth muscle cells, primary
human smooth muscle cells, vascular smooth muscle
cells, primary mouse mammary gland epithelial cells,
human lung fibroblast HEL-299 cells, and rat thyrocytes
FRTL-6. Various malignant cell types were also studied:
human osteosarcoma cells (Saos/B10 cell, Saos-2 cells),
human mammary carcinoma cells (MCF-7 cells, T47 D
cells, MDA-MB 231 cells, SKBR-3 cells), human colonic
carcinoma cells HCT-116, pancreatic carcinoma cells
Colo-357, prostate carcinoma cells PC-3, thyroid cancer
cells FTC-133, and human bladder cancer cells T 24.
The experiments were performed in comparison with
synthetic human insulin.
Aspart
This issue was addressed in the Scientific Discussion of
insulin aspart, published by the EMEA (page 4: “The
results in CHO K1 cells were essentially similar to those
of human insulin whereas the mitogenic activity of insu-
lin aspart in MCF-7 cells indicated differences to human
insulin. Subsequent analysis indicated lower activity
than initially calculated but the analysis also showed
that the results in MCF-7 cells were not sufficiently
robust for proper assessment. Newly performed studies
using human osteosarcoma B10 cells revealed essentially
similar response of insulin aspart and human insulin”
[58]).
In four studies using non-malignant cells (muscle
cells, CHO-K1 cells, MCF-10 A cells) insulin aspart
showed a similar mitogenic potency, compared to
human insulin [5,21,32,41,42]. In malignant MCF-7 cells
and T 47 D cells, insulin aspart showed similar mito-
genic potency as human insulin [32]. In malignant Saos/
B10 cells, insulin aspart showed lower mitogenic
potency [26]. In one study using the malignant MCF-7
cells, insulin aspart showed a non-significantly higher
mitogenic potency compared to human insulin [41,42].
Detemir
This issue was addressed in the Scientific Discussion of
insulin detemir, published by the EMEA (page 8: “Rela-
tive to human insulin, the albumin-corrected mitogenic
potency was 9% in CHO-K1 cells, 15% in a human mam-
mary cancer cell line (MCF-7 cells), 11% in a human
osteosarcoma cell line, and 25% in L6-IhR cells. Based on
these data, the mitogenic potency of insulin detemir in
vitro seems to be reduced relative to human insulin to
approximately the same extent as its binding affinity for
the insulin and IGF-1 receptors” [59]). Ten years later,
however, the company emphasized that “the potency esti-
mates are different between the in vivo and in vitro
conditions” [48]. There were nine studies which had
equimolar comparisons to human insulin, and one that
was based on equipotent comparison [33].
In five studies using non-malignant cells (vascular
smooth muscle cells [54], MCF-10A cells [32,41,42],
HEL-299 cells [55]), insulin detemir showed similar mito-
genic potency compared to human insulin. In one study
using non-malignant human muscular endothelial cells
[22] and L6-hlR cells [22], the mitogenic potency of insu-
lin detemir was non-significantly lower compared to
human insulin. Using the malignant MCF-7 cells, insulin
detemir showed similar mitogenic potency in two studies
[32,41,42], and higher mitogenic potency in one study
[56]. Studies using the malignant Saos/B10 cells [26], and
T24 cells [30] showed less mitogenic potency of insulin
detemir, and a study using HCT-116 cells [56] and PC-3
cells [56] showed higher mitogenic potency of insulin
detemir compared to human insulin. In the one study
using MCF-7 cells with equipotent comparison, insulin
detemir showed similar mitogenic potency compared to
human insulin [33].
Glargine
This issue was addressed in the Scientific Discussion of
insulin glargine, published by the EMEA (page 7: “...
insulin glargine might have a mitogenic potential
through binding to the IGF-1 receptor. This point of
concern was addressed in an oral explanation at the
Committee for Proprietary Medicinal Products (CPMP)
where the company highlighted that insulin glargine had
a lower mitogenic activity than the comparator B10-Asp
insulin or IGF-1 in 3 out of 4 cell assays”[60]). There
were 26 studies on this topic, all with equimolar com-
parisons to human insulin.
In 12 studies using non-malignant cells (H9 rat cardio-
myoblasts [9,28], rat-1 fibroblasts [11], primary human
muscle cells [14], primary human smooth muscle cells
[16], human coronary artery smooth muscle cells [49],
human coronary artery endothelial cells [49], vascular
smooth muscle cells [54], MCF-10 A cells [32,41,42], rat
thyrocytes FRTL-5 [34] and HepG2 cells [19]), insulin
glargine showed similar mitogenic potency compared to
human insulin. In 5 studies using non-malignant cells
(human dermal microvascular endothelial cells [13],
human mammary epithelial cells [22,25], individual pri-
mary human smooth muscle cells [16], HEL-299 cells
[55]), insulin glargine showed higher mitogenic potency
compared to human insulin. In one study using the non-
malignant L6-hlR cells [22], insulin glargine showed
lower mitogenic potency compared to human insulin.
In 6 studies using malignant cells (MCF-7 cells [50],
Colo-357 cells [17], T47 D cells [32], MDA-MB-231 cells
[29], T24 cells [31], thyroid cancer FTC-133 cells [34],
insulin glargine displayed similar mitogenic potency as
compared to human insulin. In 12 studies using malignant
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[27,32,33,41,42,56], SKBR-3 cells [27], HCT-11 cells [56]
and PC-3 cells [56], insulin glargine showed increased
mitogenic potency compared to human insulin. In one
study using Saos/B10 cells, the insulin glargine metabolite
IM showed increased mitogenic potency [46], while the
glargine metabolites M1 and M2 showed similar mitogenic
potency compared to human insulin [46].
Glulisine
This issue was addressed in the Scientific Discussion of
insulin glulisine, published by the EMEA (page 9: “(thy-
midine incorporation) was equal for insulin glulisine
and human insulin..” [61]).
Six studies using non-malignant cells (K6 myoblasts
[35], C2C12 myoblasts [23], primary human muscle cells
[15], rat-1 fibroblasts [51], MCF-10 A cells [32,43] and
mammary gland cells [43]) showed equal mitogenic
potency of insulin glulisine and human insulin, whereas
one study using MCF-10 cells showed less mitogenic
potency of insulin glulisine [24].
Two studies in malignant MCF-7 cells [32,43] showed
equal mitogenic potency of insulin glulisine and human
insulin.
Lispro
This issue was addressed in the Scientific Discussion of
insulin lispro, published by the EMEA (page 2: “In cell
growth assays using human smooth muscle cells and
human mammary epithelial cells and using... thymidine
incorporation or increases in cell number as index of
cell growth, insulin lispro was shown to be equipotent
to human insulin”[62]).
In five studies using non-malignant cells (human
mammary epithelial cells [45], rat H4-II-E hepatoma
cells [20], and MCF-10A cells [32,41,42], insulin lispro
displayed similar mitogenic potency compared to
human insulin. In one study using human smooth mus-
cle cells [44], insulin lispro displayed higher mitogenic
potency, and in another study using human smooth
muscle cells, insulin lispro displayed lower mitogenic
potency compared to human insulin [44].
In three of the studies using malignant cells (MCF-7
[32,41,42] and T 24 D [32]), insulin lispro displayed equal
mitogenic potency compared to human insulin; in one
study using Saos/B10 cells [26], insulin lispro showed
lower, and in one study using HCT-116 cells [56], insulin
lispro showed higher mitogenic potency compared to
human insulin.
Differences in anti-apoptotic activity
This issue was not specifically addressed in the Scientific
Discussions of any of the five analogues published by
the EMEA [58-62]). However, there were six publica-
tions [17,36,49,52,56,57] reporting in vitro data on the
inhibition of apoptosis by insulin analogues versus
human insulin.
Aspart
There was only one study of insulin aspart using malig-
nant INS-1 cells [36]; the inhibition of apoptosis was
similar compared to human insulin.
Detemir
There were two studies of insulin detemir, conducted
with equimolar comparisons to human insulin in malig-
nant HCT-116 cells [56,57]; in both studies, insulin
detemir inhibited apoptosis more than did human
insulin.
Glargine
There was one study using non-malignant cells (human
coronary endothelial cells [49] and human coronary artery
smooth muscle cells [49]) showing no effect on apoptosis
by either insulin glargine or human insulin. In one study
conducted with equimolar concentrations of insulin glar-
gine and human insulin in malignant Colo-357 cells [17],
inhibition of apoptosis was similar between both com-
pounds. In malignant HCT-116 cells [56,57], and malig-
nant INS-1 cells [52], insulin glargine inhibited apoptosis
stronger compared to human insulin.
Glulisine
There were two studies of insulin glulisine, conducted in
malignant INS-1 cells [36,52], showing stronger inhibition
of apoptosis by insulin glulisine compared to human
insulin.
Lispro
There were two studies of insulin lispro, conducted in
malignant INS-1 cells [36,52], one showing similar inhi-
bition [52], and one showing stronger [36] inhibition of
apoptosis by insulin lispro compared to human insulin.
Differences in intracellular signaling
The issue was not specifically addressed in the Scientific
Discussions of any of the five analogues published by the
EMEA [58-62]. However there were 12 publications
[14,23,31,35,40-43,47,54,56,57] reporting in vitro data on
intracellular signalling by insulin analogues versus human
insulin concerning the Akt-GSK-3 pathway (involved in
metabolic activity), and the Erk-MAPK pathway (involved
in proliferative activity).
Aspart
There were two studies of insulin aspart, conducted in
non-malignant MCF-10A cells and malignant MCF-7
cells [41,42], and in IGF-1 receptor-deprived mouse
fibroblasts transfected with either the human insulin
receptor A or B isoforms [40], all of which showed equal
Akt-activation and GSK-3 inactivation of insulin aspart
compared to human insulin. Erk 1/Erk 2 phosphorylation
by insulin aspart was similar to human insulin in MCF-
10A cells [41,42], but was increased in fibroblasts
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in fibroblasts expressing insulin receptor B isoform [40].
Detemir
There were five studies of insulin detemir conducted with
equimolar comparisons to human insulin [41,42,54,56,57],
and one with equipotent comparison [40].
A similar Akt-activation by insulin detemir and human
insulin was found in non-malignant MCF-10A cells
[41,42] and in non-malignant fibroblasts expressing insulin
receptor A isoform [40]. A weaker Akt-activation by insu-
lin detemir compared to human insulin was found in non-
malignant cells (3T3-L1 adipocytes [54], L6 myocytes [54],
primary hepatocytes [54], primary vascular smooth muscle
cells [54]), and in non-malignant fibroblasts expressing
insulin receptor B isoform [40].
In non-malignant cells (3T3-L1 adipocytes [54], L6 myo-
cytes [54], primary hepatocytes [54], primary vascular
smooth muscle cells [54]) GSK-3 inactivation by insulin
detemir was weaker than that by human insulin. In non-
malignant MCF-10A cells, GSK-3 inactivation was similar
by insulin detemir and human insulin [41,42]. Erk 1/Erk 2
phosphorylation by insulin detemir was equal to that by
human insulin in two studies using non-malignant cells
(MCF-10A cells [41,42] and fibroblasts expressing insulin
receptor B isoform [40]. Erk 1/Erk 2 phosphorylation was
increased by insulin detemir in fibroblasts expressing insu-
lin receptor A isoform [40].
In non-malignant cells (3T3-L1 adipocytes [54], L6 myo-
cytes [54], primary hepatocytes [54], primary vascular
smooth muscle cells [54]), MAP-kinase activation by insu-
lin detemir was weaker than that by human insulin. In
malignant cells (MCF-7 [41,42], HCT-116 [56,57]), Akt-
activation by insulin detemir was weaker than that by
human insulin. In MCF-7 cells, GSK-3 inactivation was
weaker by insulin detemir as compared to human insulin
[41,42]. Erk 1/Erk 2 phosphorylation was decreased by
detemir in MCF-7 cells [41,42] and HCT-116 cells [56,57].
In MCF-7 cells, MAP-kinase activation by detemir was
similar to that by human insulin [41,42].
Glargine
There were eight studies of insulin glargine, all of which
with equimolar comparisons to human insulin [14,31,40-
42,54,56,57]. Akt-activation by insulin glargine was similar
to that by human insulin in non-malignant primary
human muscle cells [14], 3T3-L1 adipocytes [54], L6 myo-
cytes [54], primary hepatocytes [54], primary vascular
smooth muscle cells [54], and in fibroblasts expressing
insulin receptor A isoform [40]. In non-malignant MCF-
10A cells, Akt-activation by insulin glargine was stronger
[41,42], and in fibroblasts expressing insulin receptor B
isoform it was weaker than that by human insulin [40].
GSK-3 inactivation by insulin glargine was similar to that
by human insulin in non-malignant 3T3-L1 adipocytes
[54], L6 myocytes [54], primary hepatocytes [54], primary
vascular smooth muscle cells [54], and MCF-10A cells
[41,42]. Erk 1/Erk 2 phosphorylation by insulin glargine
was equal to that by human insulin in fibroblasts expres-
sing insulin receptor B isoform [40], it was stronger in
fibroblasts expressing insulin receptor A isoform [40], and
weaker in MCF-10A cells [41,42]. MAP-kinase activation
by glargine was equal to that by human insulin in primary
human muscle cells [14] and in primary rat vascular
smooth muscle cells [54].
Glulisine
Akt-activation by insulin glulisine was similar to that by
human insulin in non-malignant rat cardiomyocytes [35],
and in fibroblasts expressing insulin receptor A isoform
[40]. Akt-activation by insulin glulisine was weaker than
that by human insulin in MCF-10A cells [43], in mouse
muscle tissue [23], in mouse liver tissue [23], and in fibro-
blasts expressing insulin receptor B isoform [40]. GSK-3
inactivation by insulin glulisine was similar to that by
human insulin in rat cardiomyocytes [35], and weaker in
MCF-10A cells [43]. Erk 1/Erk 2 phosphorylation by insu-
lin glulisine was similar to that by human insulin in MCF-
10 cells [43], and weaker in K6 myoblasts [35], in fibro-
blasts expressing insulin receptor A isoform [40], and in
fibroblasts expressing insulin receptor B isoform [40].
MAP-kinase activation by glulisine was similar to that by
human insulin in mouse muscle tissue [23], and mouse
liver tissue [23].
Lispro
Akt-activation by insulin lispro was similar to that by
human insulin in non-malignant MCF-10 A cells [41,42],
and in fibroblasts expressing insulin receptor A isoform
[40]. Akt-activation by insulin lispro was weaker than that
by human insulin in fibroblasts expressing insulin receptor
B isoform [40]. GSK-3 inactivation by lispro was similar to
that by human insulin in MCF-10A cells [41,42]. Erk 1/
Erk 2 phosphorylation by insulin lispro was similar to that
by human insulin in L6 myocytes [47], and in MCF-10A
cells [41,42]; it was weaker in fibroblasts expressing insulin
receptor B isoform [40], and stronger in fibroblasts expres-
sing insulin receptor A isoform [40].
The studies mentioned above are listed in Table 1.
Differences in effects on thrombocytes
The issue was not specifically addressed in the Scientific
Discussions of any of the five analogues published by
the EMEA [58-62]. However, there were two publica-
tions [37,38] that compared the effects of insulin analo-
gues and human insulin on thrombocyte function.
Aspart
Inhibition of platelet aggregation was stronger than that
by human insulin; both compounds affected platelet
aggregation via PI-3 K activation [37].
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Inhibition of platelet aggregation was stronger than that
by human insulin; both compounds affect platelet aggre-
gation via PI-3 K activation [38].
Differences in effects on protein degradation
This issue was not specifically addressed in the Scientific
Discussion of any of the five analogues published by the
EMEA [58-62]. However, there were two publications
[18,19] on this topic.
Glargine
Inhibition of protein degradation in HepG2 cells was
less than that by human insulin [19].
Lispro
Inhibition of protein degradation in H4-II-E hepatoma
cells was much stronger than that by human insulin,
and inhibition of protein degradation in Hep2G cells
and in L6 cells was similar to that by human insulin
[18].
Differences in intracellular internalization and
degradation
The issue was not specifically addressed in the Scientific
Discussion of any of the five analogues published by the
EMEA [58-62]. However, there were four publications
[10,19,20,35] on this topic.
Glargine
Internalization into HepG2 cells was similar to that of
human insulin, whereas degradation was much less
compared to human insulin [19].
Glulisine
Internalization into and degradation by K6 rat myoblasts
was less compared to human insulin [35].
Lispro
Internalization into rat hepatocytes was similar to that
of human insulin [20]; degradation by insulin degrading
enzyme (IDE) was similar to that of human insulin
[10,20].
Miscellaneous
Effect on gene expression
This issue was not specifically addressed in the Scientific
Discussion of any of the five analogues published by the
EMEA [58-62]. However, there were three publications
[12,41,43] on this topic.
Detemir
In 3T3-L1 preadipocytes, the effect of insulin detemir
on the gene expression of leptin and PPAR-Gamma-2
Table 1 Bioactivities of insulin analogues versus human insulin
Aspart Detemir Glargine Glulisine Lispro
lower 12,26,48,54 9,19,25,26
metabolic activity equal 21,26,53 13,14,55 15,35 26,5
higher
lower 26 22,26,30 22 26,44
mitogenic activity equal 5,21,32,41,42 32,33,41,42,54,55 9,11,14,16,17,19,28,29,31, 32,34,41,42,49,50,54 15,23,32,35,43,51 20,32,41,42,45
higher 41,42 56 13,16,21,22,25-27,32,33,39, 41,42,46,55,56 44,56
lower
apoptosis inhibition equal 36 17,49 52
higher 56,57 52,56,57 36,52 36
lower 40-42,54,56,57 40 23,40,43 40
Akt-activation equal 40-42 40-42 14,40,54 35,40 40-42
higher 41,42
lower 41,42,54 41,42,54 43 41,42
GSK-3 inactivation equal 40-42 41,42 35
higher
lower 40 41,42,56,53 41,42 23,40,43 40
Erk-phosphorylation equal 41,42 40-42 40 35,40 41,42,47
higher 40 40 40 40
lower 54
MAP-kinase activation equal 41,42 14,54 23
higher
Compliation of reports (numbers refer to the publications cited in the reference list) on bioactivities of the insulin analogues aspart, detemir, glargine, glulisine,
and lispro versus human insulin.
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[12].
Glargine
In MCF-7 cells, insulin glargine induced a higher expres-
sion of the Cyclin D1 gene, compared to human insulin
[41].
Glulisine
In HepG2 cells, neither insulin glulisine nor human
insulin induced hexokinase-4 expression [43]. In HepG2
cells, hexokinase-2 expression was induced to the same
extent by both 150 nmol human insulin and insulin glu-
lisine; no effect of either compound at lower concentra-
tions was observed in HepG2 cells or MCF-7 cells [43].
Addendum: differences in bioactivity between native
porcine or bovine insulin and synthetic human insulin
For comparison, the bioactivities of synthetic human
insulin versus native animal insulin (bovine and porcine)
are reported, as retrieved from six publications
[32,41-43,63,64].
Metabolic potency
In human and rat adipocytes, porcine insulin showed
slightly higher metabolic potency (in terms of lipogen-
esis in rat epididymal and human subcutaneous fat
cells), as compared to synthetic (recombinant DNA)
human insulin (Humulin
®, Eli Lilly, Indianapolis, IN,
USA) [64].
Mitogenicity
In MCF-7 cells, bovine insulin showed slightly less mito-
genic potency compared to synthetic human insulin
(Actrapid
®, NovoNordisk, Bagsvaerd, Denmark),
whereas in MCF-10A and T47 D cells, bovine insulin
showed a similar mitogenic potency to human insulin
[32,41-43]. In bovine dermal fibroblasts GM06034 and
GM06035, bovine insulin and synthetic human insulin
(Humulin
®) displayed a similar mitogenic potency [63].
Intracellular signalling
In MCF-7 and MCF-10A cells, bovine insulin showed a
slightly weaker Erk 1/2 phosphorylation compared to
synthetic human insulin (Actrapid
®), whereas the effect
on Akt-phosphorylation and GSK 3 alpha/beta-phos-
phorylation was similar to that of synthetic human insu-
lin [41-43].
Gene expression
In HepG2 cells, neither bovine nor human insulin
induced hexokinase 4 expression [43].
Discussion
Our schematic presentation shows that in the 1990s
most in vitro studies were industry-sponsored ones
(except for study [5]), and were performed using non-
malignant cells, whereas in later years, the majority of
studies were performed using malignant cells, and many
of them were carried out by industry-independent inves-
tigators. This change in direction may have been
brought about by the Points to Consider Document of
the EMEA [65] of 2001, which particularly requested
studies using malignant cell lines, or malignant tissues,
or animal models of malignancies to prove the safety of
insulin analogues in terms of tumour growth promotion.
The rationale for this request was that non-malignant
and malignant tissues may respond differently to stimu-
lation by insulin or insulin analogues, due to differences
in the expression (or the function) of insulin receptors
and IGF-1 receptors between non-malignant and malig-
nant tissues.
Moreover, we found that the metabolic bioactivity of
insulin analogues was studied exclusively on benign pri-
mary fat cells, or fat cell lines. According to these inves-
tigations, the analogue insulins aspart, glulisine and
lispro were shown to have equal metabolic potencies to
human insulin, whereas the analogues glargine and dete-
mir considerably reduced metabolic activity. The
growth-promoting bioactivity, e.g. effects on mitogeni-
city and apoptosis, showed equal potencies of the insulin
analogues and human insulin in most circumstances-
when studied in benign cells. Different effects, particu-
larly on mitogenicity and apoptosis, only became appar-
ent when the insulin analogues and human insulin were
studied in malignant cells. Intracellular signalling was
examined for all of the insulin analogues, and consider-
able differences to human insulin were found in both
non-malignant and malignant cells.
Of note are the considerable inconsistencies between
the findings of various studies that sometimes seemed
contradictory. These discrepancies were most likely due
to methodological differences between the various study
settings and designs, such as the following:
The type of cells studied
It was shown that a high ratio of IGF-1 receptors to
insulin receptors is required for a strong mitogenic
effect of glargine [66]. It is likely that this applies not
only to cell-lines, but also to primary cells, and to pri-
mary tumour cells and tissues. Considerable differences
in receptor expression may exist between health and
disease [67,68], and between individuals [16]. Many
human cancers overexpress IGF-1 receptors, particular
insulin receptors, and hybrid receptors 67, 69], in con-
trast to healthy tissues. Thus, cancer cell-lines or cancer
tissue may be more susceptible to growth stimulation by
insulin or insulin analogues than healthy tissue, and
some cancer cell-lines may be more susceptible than
others. Furthermore, metabolic potency studies may
yield different results when performed in rat epididymal
fat cells or in human subcutaneous fat cells [64].
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Some authors used high glucose concentrations, and
some used low glucose concentrations in the cell cul-
tures. The concentration of glucose may have a signifi-
cant effect on the growth of cells in culture [70].
Moreover, the presence or absence of albumin, or of fetal
calf serum (FCS) affects cell growth and the susceptibility
of cells to growth factors or insulin: 10% FCS stimulates
cell growth as much as does 10 nmol/l IGF-1 [5,63]. The
content of insulin, oestrogen and IGF-1, for example, in
FCS is rarely indicated by the manufacturer, and may
vary between batches. Thus, starved cell cultures may
yield different results compared to FCS-fed (i.e. maxi-
mally growing) cells in terms of stimulation by insulin or
IGF-1.
Presence of albumin in the assay
The study data with detemir were particularly confusing
because this analogue was sometimes compared to
human insulin on an equimolar basis (which is inap-
propriate, because detemir in equipotent doses requires
4 times the molar concentration compared to human
insulin). Moreover, in the presence of albumin the activ-
ity of detemir is dramatically reduced [54] and not all
studies on detemir appropriately accounted for this phe-
nomenon. Furthermore, the albumin species plays a
role, for detemir binding to albumin differs according to
the albumin species (i.e. it differs in dogs versus rabbits
or pigs etc.). Hence, it could be argued that most of the
previous in vitro studies comparing insulin detemir with
other insulins are basically uninterpretable.
The concentration and the EC50 value of the ligand
under study
The concentrations of insulin and the insulin analogues
played a major role in the outcome of the experiments -
low concentrations and high concentrations may yield
qualitatively different cell responses. A comparison of
bioactivities based on EC50 values rather than on equi-
molar concentrations might be preferable.
The duration of cell culture studies
The studies were carried out over varying time intervals,
ranging from less than 1 hour to several days. In some
studies, insulin or the insulin analogues were supple-
mented only once, whereas in other studies they were
supplemented repeatedly (taking into account the fact
that insulin degradation may occur in the culture).
These aspects may have affected the performance of the
assays.
The heterogeneity in methods and outcomes suggests
that a standardization of the procedures for in vitro
examinations of insulin analogues would be required in
order to make the data more comparable. Whether
these (and possible additional) in vitro differences in
bioactivity between human insulin and the insulin analo-
gues aspart, detemir, glargine, glulisine, and lispro trans-
late into clinical outcomes remains to be elucidated.
Patient populations with particular genetic make-up
may be particularly susceptible [71]. There are already
some indications that the in vitro differences might mat-
ter in clinical practice [33], and that other differences as
disclosed by in vivo studies (e,g, glargine may increase
serum IGF-1 concentrations in diabetic patients [72],
detemir largely increases serum insulin levels [48,73]
and may accumulate in the liver and the brain [74])
might matter, too.
In conclusion, the schematic presentation of the cur-
rently available in vitro data (except for receptor studies)
on the differences in bioactivity between human insulin
and the insulin analogues aspart, detemir, glargine, gluli-
sine, and lispro displays a variety of abnormal activities of
the analogues. The data- albeit suffering from heteroge-
neity between the assays-suggests that manipulation of
the insulin molecule in order to improve its absorption
from the subcutaneous tissue may cause unphysiological
bioactivities with hitherto unknown consequences for the
diabetic user as well as for the laboratory researcher.
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